Related Experiment Video
Updated: Jun 2, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis
Guo-Yuan Liu1, De-Ke Jiang, Su-Qin Shen
1The State Key Laboratory of Genetic Engineering, Fudan University, Shanghai, China.
Archives of Medical Research
|May 14, 2011
Summary
The MDM2 309 G allele is linked to increased hepatocellular carcinoma (HCC) risk. This meta-analysis of five studies suggests the G allele is a significant risk factor for HCC development.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- The murine double minute 2 (MDM2) gene regulates tumor protein p53.
- A specific polymorphism, MDM2 SNP309 T>G, may affect MDM2 expression and tumor formation.
- Previous studies on the association between MDM2 SNP309 and hepatocellular carcinoma (HCC) risk are conflicting.
Purpose of the Study:
- To conduct a meta-analysis to clarify the association between the MDM2 SNP309 T>G polymorphism and HCC risk.
- To provide a comprehensive assessment of the MDM2 polymorphism's role in HCC development.
Main Methods:
- A systematic literature search was performed on PubMed to identify eligible case-control studies.
- Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated.
- Fixed- and random-effects models were employed to assess the association across genetic models.
Main Results:
- Five case-control studies comprising 738 cases and 1014 controls were included.
- Significant associations were detected for all genetic models, indicating the MDM2 309 G allele increases HCC risk.
- Subgroup analyses based on Hardy-Weinberg equilibrium, sample size, and ethnicity reinforced these significant associations.
Conclusions:
- The MDM2 309 G allele is likely a significant risk factor for hepatocellular carcinoma.
- Further large-scale, ethnically diverse studies are warranted to confirm these findings.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...